Conjugates of a novel 7-substituted camptothecin with RGD-peptides as αvβ3 integrin ligands: An approach to tumor-targeted therapy

Bioconjugate Chemistry

Volumn 21, Issue 11, 2010, Pages 1956-1967

  Dal Pozzo, Alma ^a   Esposito, Emiliano ^a   Ni, Minghong ^a   Muzi, Laura ^a   Pisano, Claudio ^b   Bucci, Federica ^b   Vesci, Loredana ^b   Castorina, Massimo ^b   Penco, Sergio ^b  

^a Istituto di Ricerche Chimiche e Biochimiche G Ronzoni   (Italy)

^b Sigma Tau SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN DERIVATIVE; CYCLOPEPTIDE; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG CONFORMATION; DRUG CONJUGATION; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; TUMOR CELL;

MURINAE;

EID: 78649300912     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc100097r     Document Type: Article

References (34)

1. Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlank, R. I., Gearing, R. P., Bovee, T. D., Siegall, C. B., Francisco, J. A., Wahl, A. F., Meyer, D. I., and Senter, P. D. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy Nat. Biotechnol. 21, 778-784
2. Jaracz, S., Chen, J., Kuznetsova, L. V., and Ojima, I. (2005) Recent advances in tumor- targeting drug conjugates Biorg. Med. Chem. 13, 5043-5054
3. Temming, K., Meyer, D. L., Zabinski, R., Dijkers, E. C. F., Poelstra, K., Molema, G., and Kok, R. J. (2006) Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels Bioconjugate Chem 17, 1385-1394
4. Chari, R. V. J. (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs Acc. Chem. Res. 41, 98-107
5. Ducry, L. and Stump, B. (2010) Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies Bioconjugate Chem. 21, 5-13
6. Hamman, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H. R., Upeslacis, J., Shochat, D., Mountain, A., Flowers, D. A., and Bernstein, I. (2002) Gentuzumab ozogamicin: a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia Bioconjugate Chem 13, 47-58
7. Okarvi, S. M. (2004) Peptide-based radiopharmaceutical; future tools for diagnostic imaging of cancer and other diseases Med. Res. Rev. 24, 357-397
8. Zaccaro, L., del Gatto, A., Pedone, C., and Saviano, M. (2009) Peptides for tumor therapy and diagnosis: current status and future directions Curr. Med. Chem. 16, 780-795
9. Cristofanilli, M., Charnsangavej, C., and Hortobagyi, G. N. (2002) Angiogenesis modulation in cancer research: novel clinical approaches Nat. Rev. Drug Discovery 1, 415-426
10. Jain, R. K. (2003) Molecular regulation of vessel maturation Nat. Med. 9, 685-693
11. Ruoslathi, E. and Pierschbacher, M. D. (1987) New perspective in cell adhesion RGD and integrins Science 238, 491-497
12. v integrins as receptors for tumor targeting by circulating ligands Nat. Biotechnol. 15, 542-546
13. Arap, W., Pasqualini, R., and Ruoslathi, E. (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model Science 279, 377-380
14. Haubner, R. and Wester, H. J. (2004) Radiolabelled traces for imaging of tumor angiogenesis and evaluation of antiangiogenic therapies Curr. Pharm. Des. 10, 1439-455
15. Temming, K., Schiffelers, R. M., Molema, G., and Kok, R. J. (2005) RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumor vasculature Drug Resistance Updates 8, 381-402
16. Chen, X., Plasencia, C., Hou, Y., and Neamati, N. (2005) Synthesis and biological evaluation of dimeric RGD peptide-placlitaxel conjugate as a model for integrin-targeted drug delivery J. Med. Chem. 48, 1098-1106
17. Meyer, A., Auernheimer, J., Modlinger, A., and Kessler, H. (2006) Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting Curr. Pharm. Des 12, 2723-2747
18. 3 Bioconjugate Chem. 19, 1414-422
19. McNerny, A. M., Kukowska-Latallo, J. F., Mullen, D. G., Wallace, J. M., Desai, A. M., Shukla, R., Huang, B., Holl, M. M. B., and Baker, J. R. (2009) RGD dendron bodies: synthetic avidity agents with defined and potentially interchangeable effector sites that can substitute for antibodies Bioconjugate Chem. 20, 1853-1859
20. Pisano, C., De Cesare, M., Beretta, G. L., Zuco, V., Pratesi, G., Penco, S., Vesci, L., Foderà, R., Ferrara, F. F., Guglielmi, M. B., Carminati, P., Dalla valle, S., Morini, G., Merlini, L., Orlandi, A., and Zumino, F. (2008) Preclinical profile of antitumor activity of a novel Hydrophilic camptothecin, ST1968 Mol. Cancer Ther. 7, 2051-2059
21. Conover, C. D., Greenwald, R. B., Pendri, A., Gilbert, K. W., and Shum, K. L. (1998) Camptothecin delivery systems. Enhanced efficacy and tumor accumulation of camptothecin following its conjugation to poly(ethylene glycol) via a glycine linker Cancer Chemother. Pharmacol 42, 407-414
22. Caiolfa, V. R., Zamai, M., Fiorino, A., Frigerio, E., Pellizzoni, C., d'Argi, R., Ghigleri, A., Castelli, M. G., Farao, M., Pesenti, E., Gigli, M., Angelucci, F., and Suarato, A. (2000) Polymer-bound camptothecin: initial biodistribution and antitumor activity studies J. Controlled Release 65, 105-119
23. Lerchen, H. G., Baumgarten, J., von dem Bruch, K., Lehmann, T. E., Sperzel, M., Kempka, G., and Fiebig, H. H. (2001) Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents J. Med. Chem. 44, 4186-4195
24. Dal Pozzo, A., Ni, M. H., Esposito, E., Dallavalle, S., Musso, L., Bargiotti, A., Pisano, C., Vesci, L., Bucci, F., Castorina, M., Foderà, R., Giannini, G., and Penco, S. (2010) Novel tumor-targeted RGD peptide-camptothecin conjugates: synthesis and biological evaluation Biorg. Med. Chem. 18, 64-72
25. Duncan, R., Cable, H. C., Lloyd, J. B., Rejmanova, P., and Kopecek, J. (1983) Polymers containing enzymatically degradable bond, 7. Design of oligopeptides side chains in poly N-2- hydroxypropyl)methacrylamide copolymers to promote degradation by lysosomal enzymes Macromol. Chem. 184, 1997-2008
26. Dubowchik, G. M. and Firestone, R. A. (1998) Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of Doxorubicin Biorg. Med.Chem. Lett. 8, 3341-3346
27. Dubowchik, G. M., Firestone, R. A., Padilla, L., Willner, D., Hofstead, S. J., Mosure, K., Knipe, J. O., Lash, S. J., and Trail, P. A. (2002) Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro antitumor activity Bioconjugate Chem. 13, 858-869
28. Shiose, Y., Kuga, H., Ohki, H., Ikeda, M., Yamashita, F., and Hashida, M. (2009) Systematic research of peptide spacers controlling drug release from macromolecular prodrugs system, carboxymethyldextran-polyalcohol-peptide drug conjugates Bioconjugate Chem. 20, 60-70
29. 3 integrin for a new cancer therapy Angew. Chem. 36, 1374-1389
30. Dal Pozzo, A., Penco, S., Giannini, G., Tinti, O., Pisano, C., Vesci and, L., and Ni, M. H. Cyclopeptide derivatives with anti-integrin activity, EP 1 751 176 B1, October 3, 2010.
31. Carl, P. L., Chakravarty, P. K., and Katzenellenbogen, J. A. (1980) A novel connector linkage applicable in prodrug design J. Med. Chem. 24, 479-480
32. Wang, P., Layfield, R., Landon, M., Mayer, R. J., and Ramage, R. (1998) Transfer active ester condensation: A novel technique for peptide segment coupling Tetrahedron Lett. 85, 8711-8714 (Pubitemid 28496840)
33. Kolb, H. C. and Sharpless, K. B. (2003) The growing impact of click chemistry on drug discovery Drug Discovery Today. 8, 1128-1137
34. Kitov, P. I. and Bundle, D. R. (2003) On the nature of multivalency effect: a thermodynamic model J. Am. Chem. Soc. 125, 16271-16284